SN
TEVA icon

Sittner & Nelson’s Teva Pharmaceuticals TEVA Stock Holding History

Sittner & Nelson’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52K Hold
45
– – ﹤0.01% 550
2026
Q1 		$1.36K Hold
45
– – ﹤0.01% 531
2025
Q4 		$1.56K Buy
+45
New +$1.11K ﹤0.01% 489

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Sittner & Nelson's TEVA Position: Q2 2026 in Review

Sittner & Nelson held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 45 shares worth $1.52K. The position accounts for ﹤0.01% of the portfolio, ranked #550.

Sittner & Nelson first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.56K in Q4 2025. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Sittner & Nelson held 45 shares of Teva Pharmaceuticals worth $1.52K as of Q2 2026.
  • Sittner & Nelson left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Sittner & Nelson's portfolio in Q2 2026, its #550 holding.
  • Sittner & Nelson first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Sittner & Nelson's Teva Pharmaceuticals position peaked at $1.56K in Q4 2025.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.